Cardiff Oncology price to sales ratio CRDF

Market value divided by revenue over the last twelve months, since 2013.

Today, Oct 23, 2026: 139×
10-year median: 85.2×
Against its 10-year history: 60th; percentile: 0 is its lowest day, 100 its highest
10-year range: 7.1× to 200×
Peer median: 1.4×

Cardiff Oncology's price to sales ratio is 139× as of Oct 23, 2026.

That is above its ten-year median of 85.2×, close to the middle of its last ten years.

Over that time it ranged from 7.1× in Jul 2018 to 200× in Aug 2023.

The median for 10 healthcare stocks of a similar size is 1.4×.

Price to sales ratio over time

median 85.2×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	139×	108×	198×
2025	n/m a value too high to mean anything
2024	171×	145×	198×
2023	144×	97.1×	200×
2022	160×	144×	181×
2021	n/m a value too high to mean anything
2020	169×	18.4×	178×
2019	23.1×	12.1×	51.0×
2018	26.1×	7.1×	43.8×
2017	30.4×	24.5×	187×
2016	164×	164×	195×
2015	n/m a value too high to mean anything
2014	n/m a value too high to mean anything
2013	185×	185×	198×

Against its peers

Companies in Healthcare nearest Cardiff Oncology's size, closest first, today.

Company	Price to sales ratio
CRDFCardiff Oncology	139×
LFVNLifevantage	0.4×
SPROSpero Therapeutics	1.4×
APTAlpha Pro Tech	0.9×
ICCCImmucell	3.0×
KEQUKewaunee Scientific	0.3×
ATNMActinium Pharmaceuticals	n/m
NEPHNephros	1.9×
PDEXPro DEX	2.6×
PLXProtalix BioTherapeutics	2.5×
NATRNatures Sunshine Products	0.4×
Peer median	1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Cardiff Oncology

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.